Literature DB >> 19373443

Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

João Paulo Capela1, Helena Carmo, Fernando Remião, Maria Lourdes Bastos, Andreas Meisel, Félix Carvalho.   

Abstract

"Ecstasy" [(+/-)-3,4-methylenedioxymethamphetamine, MDMA, XTC, X, E] is a psychoactive recreational hallucinogenic substance and a major worldwide drug of abuse. Several reports raised the concern that MDMA has the ability to induce neurotoxic effects both in laboratory animals and humans. Despite more than two decades of research, the mechanisms by which MDMA is neurotoxic are still to be fully elucidated. MDMA induces serotonergic terminal loss in rats and also in some mice strains, but also a broader neuronal degeneration throughout several brain areas such as the cortex, hippocampus, and striatum. Meanwhile, in human "ecstasy" abusers, there are evidences for deficits in seronergic biochemical markers, which correlate with long-term impairments in memory and learning. There are several factors that contribute to MDMA-induced neurotoxicity, namely, hyperthermia, monoamine oxidase metabolism of dopamine and serotonin, dopamine oxidation, the serotonin transporter action, nitric oxide, and the formation of peroxinitrite, glutamate excitotoxicity, serotonin 2A receptor agonism, and, importantly, the formation of MDMA neurotoxic metabolites. The present review covered the following topics: history and epidemiology, pharmacological mechanisms, metabolic pathways and the influence of isoenzyme genetic polymorphisms, as well as the acute effects of MDMA in laboratory animals and humans, with a special focus on MDMA-induced neurotoxic effects at the cellular and molecular level. The main aim of this review was to contribute to the understanding of the cellular and molecular mechanisms involved in MDMA neurotoxicity, which can help in the development of therapeutic approaches to prevent or treat the long-term neuropsychiatric complications of MDMA abuse in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19373443     DOI: 10.1007/s12035-009-8064-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  473 in total

1.  A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration.

Authors:  M Shankaran; G A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  1999-11       Impact factor: 4.530

2.  Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

Authors:  R D Crean; S A Davis; S N Von Huben; C C Lay; S N Katner; M A Taffe
Journal:  Neuroscience       Date:  2006-07-28       Impact factor: 3.590

3.  Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants.

Authors:  S Ramamoorthy; R D Blakely
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

4.  Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules.

Authors:  Ikuko Miyazaki; Masato Asanuma; Francisco J Diaz-Corrales; Masaya Fukuda; Kiyoyuki Kitaichi; Ko Miyoshi; Norio Ogawa
Journal:  FASEB J       Date:  2006-01-10       Impact factor: 5.191

5.  Restraint as a stressor in mice: against the dopaminergic neurotoxicity of D-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection.

Authors:  E A Johnson; D S Sharp; D B Miller
Journal:  Brain Res       Date:  2000-09-01       Impact factor: 3.252

6.  Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.

Authors:  J P Spencer; P Jenner; S E Daniel; A J Lees; D C Marsden; B Halliwell
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

7.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine.

Authors:  U V Berger; X F Gu; E C Azmitia
Journal:  Eur J Pharmacol       Date:  1992-05-14       Impact factor: 4.432

8.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

9.  The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine.

Authors:  G M Farfel; G L Vosmer; L S Seiden
Journal:  Brain Res       Date:  1992-11-06       Impact factor: 3.252

Review 10.  Progress in monoamine oxidase (MAO) research in relation to genetic engineering.

Authors:  Toshiharu Nagatsu
Journal:  Neurotoxicology       Date:  2004-01       Impact factor: 4.294

View more
  76 in total

1.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

Review 2.  Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage.

Authors:  Byoung-Joon Song; Kwan-Hoon Moon; Vijay V Upreti; Natalie D Eddington; Insong J Lee
Journal:  Curr Pharm Biotechnol       Date:  2010-08       Impact factor: 2.837

3.  Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors:  Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

4.  In vitro metabolism of 3,4-methylenedioxymethamphetamine in human hepatocytes.

Authors:  Corinne Ramaley; Susan C Leonard; Jeffrey D Miller; Denita Takesha-Mashia Wilson; Sai Y Chang; Qingyu Chen; Feng Li; Chengan Du
Journal:  J Anal Toxicol       Date:  2014-03-28       Impact factor: 3.367

5.  MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.

Authors:  Giulia Costa; Nicola Simola; Micaela Morelli
Journal:  Psychopharmacology (Berl)       Date:  2014-04-01       Impact factor: 4.530

6.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

Review 7.  The preclinical pharmacology of mephedrone; not just MDMA by another name.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 8.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

9.  Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Authors:  Norbert Gyongyosi; Brigitta Balogh; Zita Katai; Eszter Molnar; Rudolf Laufer; Kornelia Tekes; Gyorgy Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2010-01-06       Impact factor: 3.575

10.  Attenuation of ecstasy-induced neurotoxicity by N-acetylcysteine.

Authors:  Sara Soleimani Asl; Bita Saifi; Abolhasan Sakhaie; Somayeh Zargooshnia; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2014-08-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.